Evidence map›Paper›PMID 38435480›Full record

ArticleSovremennye tekhnologii v meditsine2023

Application of Magnetic Particles for Fast Determination of Immunoreactive Fraction of

K O Avrov, S V Shatik, V V Zaitsev, R I Al-Shehadat, O A Shashkova, L A Terekhina, I S Malakhov, M P Samoylovich

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sovremennye tekhnologii v meditsine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
  3. Cell Model for Testing Pharmaceuticals Targeting Human PD-L1.Sovremennye tekhnologii v meditsine · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 4 countries.

K O AvrovSenior Researcher, Laboratory of Hybridome Technology; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
S V ShatikHead of the Department of Cyclotron-Produced Radiopharmaceuticals; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
V V ZaitsevHead of the Group for Radiopharmaceuticals Synthesis; Leading Technologist, Department of Cyclotron-Produced Radiopharmaceuticals; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
R I Al-ShehadatGeneral Director; Innova plus LLC, 13 Kalinina St., Lit. A, Office 18-N, Saint Petersburg, 197198, Russia.
O A ShashkovaSenior Researcher, Laboratory of Hybridome Technology; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
L A TerekhinaResearcher, Laboratory of Hybridome Technology; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
I S MalakhovSenior Researcher, Laboratory of Hybridome technology; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
M P SamoylovichChief Researcher; Head of the Laboratory of Hybridome technology; A.M. Granov Russian Research Center of Radiology and Surgical Technologies of the Ministry of Health of the Russian Federation, 70 Leningradskaya St., Saint Petersburg, Pesochniy Settlement, 197758, Russia.
St Petersburg University · RURussian Scientific Center of Radiology and Surgical Technologies · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantification of the immunoreactive fraction (IRF) of radioactive isotope-labeled antibodies or their fragments is necessary to assess the specific activity of radiopharmaceuticals. Traditionally, cells expressing the target molecules on their surface are used to determine IRF, but such analysis is time-consuming and has difficulties with standardization. Materials and Methods: Commercially available magnetic particles coated with protein A have been used in our study. The antigen conjugated with the Fc fragment (PD-L1-Fc) was immobilized on the particles. The IRF value of Results: The specificity of the

Indexed as

ImmunoconjugatesSingle-Domain AntibodiesB7-H1 AntigenGallium RadioisotopesMagnetic PhenomenaRadiopharmaceuticalsB7-H1 AntigenGallium RadioisotopesImmunoconjugatesRadiopharmaceuticalsSingle-Domain Antibodiesimmunoreactive fractionmagnetic particlesradioimmunoconjugateVHH antibodies

Identifiers

PMID38435480
PMCPMC10904357
OpenAlexW4382727203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.